

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/855,597	05/15/2001	Wai C. Wong	45704-GA/JPW/BJA	9652

7590 01/14/2002

John P. White
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, NY 10036

EXAMINER

COLEMAN, BRENDA LIBBY

ART UNIT

PAPER NUMBER

1624

DATE MAILED: 01/14/2002

6

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.
09/855,597

Applicant(s)
WONG et al.

Examiner
Brenda Coleman

Art Unit
1624



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on _____.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 13-23, 25, 27-31, 41, 42, and 45 is/are pending in the application.
- 4a) Of the above, claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claims 13-23, 25, 27-31, 41, 42, and 45 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are objected to by the Examiner.
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

- 13) ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
- a) ☐ All b) ☐ Some* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

*See the attached detailed Office action for a list of the certified copies not received.

- 14) ☒ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

- 15) ☐ Notice of References Cited (PTO-892) 18) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 16) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 19) ☐ Notice of Informal Patent Application (PTO-152)
- 17) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____ 20) ☐ Other: _____

Art Unit: 1624

Election/Restriction

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 13-18, 20-23, 25, 27-31, 41, 42 and 45, drawn to compounds, compositions and method of use of the compounds where R_3 is the first moiety in the definition of R_3 and it is bonded to the pyrimidine ring through the nitrogen atom.
- II. Claims 13-15, 20-23, 25, 27-31, 41, 42 and 45, drawn to compounds, compositions and method of use of the compounds where R_3 is the second moiety in the definition of R_3 and it is bonded to the pyrimidine ring through the nitrogen atom.
- III. Claims 13-15, 20-23, 25, 27-31, 41, 42 and 45, drawn to compounds, compositions and method of use of the compounds where R_3 is the third moiety in the definition of R_3 and it is bonded to the pyrimidine ring through the nitrogen atom.
- IV. Claims 13-15, 20-23, 25, 27-31, 41, 42 and 45, drawn to compounds, compositions and method of use of the compounds where R_3 is the fourth moiety in the definition of R_3 and it is bonded to the pyrimidine ring through the nitrogen atom.
- V. Claims 13-15, 20-23, 25, 27-31, 41, 42 and 45, drawn to compounds, compositions and method of use of the compounds where R_3 is the fifth moiety in

Art Unit: 1624

the definition of R_3 and it is bonded to the pyrimidine ring through the nitrogen atom.

- VI. Claims 13-15, 20-23, 25, 27-31, 41, 42 and 45, drawn to compounds, compositions and method of use of the compounds where R_3 is the sixth moiety in the definition of R_3 and it is bonded to the pyrimidine ring through the nitrogen atom.
- VII. Claims 13-15, 20-23, 25, 27-31, 41, 42 and 45, drawn to compounds, compositions and method of use of the compounds where R_3 is the seventh moiety in the definition of R_3 and it is bonded to the pyrimidine ring through the nitrogen atom.
- VIII. Claims 13-15, 20-23, 25, 27-31, 41, 42 and 45, drawn to compounds, compositions and method of use of the compounds where R_3 is the eighth moiety in the definition of R_3 and it is bonded to the pyrimidine ring through the nitrogen atom.
- IX. Claims 13-15, 20-23, 25, 27-31, 41, 42 and 45, drawn to compounds, compositions and method of use of the compounds where R_3 is the ninth moiety in the definition of R_3 and it is bonded to the pyrimidine ring through the nitrogen atom.
- X. Claims 13-15, 20-23, 25, 27-31, 41, 42 and 45, drawn to compounds, compositions and method of use of the compounds where R_3 is the tenth moiety in

Art Unit: 1624

the definition of R_3 and it is bonded to the pyrimidine ring through the nitrogen atom.

- XI. Claims 13-15, 19-23, 25, 27-31, 41, 42 and 45, drawn to compounds, compositions and method of use of the compounds where R_3 is the eleventh moiety in the definition of R_3 and it is bonded to the pyrimidine ring through the nitrogen atom.
- XII. Claims 13-15, 20-23, 25, 27-31, 41, 42 and 45, drawn to compounds, compositions and method of use of the compounds where R_3 is the first moiety in the definition of R_3 and it is bonded to the pyrimidine ring through the carbon atom.
- XIII. Claims 13-15, 20-23, 25, 27-31, 41, 42 and 45, drawn to compounds, compositions and method of use of the compounds where R_3 is the second moiety in the definition of R_3 and it is bonded to the pyrimidine ring through the carbon atom.
- XIV. Claims 13-15, 20-23, 25, 27-31, 41, 42 and 45, drawn to compounds, compositions and method of use of the compounds where R_3 is the third moiety in the definition of R_3 and it is bonded to the pyrimidine ring through the carbon atom.
- XV. Claims 13-15, 20-23, 25, 27-31, 41, 42 and 45, drawn to compounds, compositions and method of use of the compounds where R_3 is the fourth moiety

Art Unit: 1624

in the definition of R_3 and it is bonded to the pyrimidine ring through the carbon atom.

XVI. Claims 13-15, 20-23, 25, 27-31, 41, 42 and 45, drawn to compounds, compositions and method of use of the compounds where R_3 is the fifth moiety in the definition of R_3 and it is bonded to the pyrimidine ring through the carbon atom.

XVII. Claims 13-15, 20-23, 25, 27-31, 41, 42 and 45, drawn to compounds, compositions and method of use of the compounds where R_3 is the sixth moiety in the definition of R_3 and it is bonded to the pyrimidine ring through the carbon atom.

XVIII. Claims 13-15, 20-23, 25, 27-31, 41, 42 and 45, drawn to compounds, compositions and method of use of the compounds where R_3 is the seventh moiety in the definition of R_3 and it is bonded to the pyrimidine ring through the carbon atom.

XIX. Claims 13-15, 20-23, 25, 27-31, 41, 42 and 45, drawn to compounds, compositions and method of use of the compounds where R_3 is the eighth moiety in the definition of R_3 and it is bonded to the pyrimidine ring through the carbon atom.

XX. Claims 13-15, 20-23, 25, 27-31, 41, 42 and 45, drawn to compounds, compositions and method of use of the compounds where R_3 is the ninth moiety in

Art Unit: 1624

the definition of R_3 and it is bonded to the pyrimidine ring through the carbon atom.

XXI. Claims 13-15, 20-23, 25, 27-31, 41, 42 and 45, drawn to compounds, compositions and method of use of the compounds where R_3 is the tenth moiety in the definition of R_3 and it is bonded to the pyrimidine ring through the carbon atom.

XXII. Claims 13-15, 19-23, 25, 27-31, 41, 42 and 45, drawn to compounds, compositions and method of use of the compounds where R_3 is the eleventh moiety in the definition of R_3 and it is bonded to the pyrimidine ring through the carbon atom.

The inventions are distinct, each from the other because of the following reasons:

Groups I-XXII are directed to structurally dissimilar compounds such that the variable core created by the varying definitions of R_3 in first formula and the second formula do not belong to a recognized class of chemical compounds in the art, and references anticipating one invention, would not render obvious the others, for example piperidine is different from a tricyclic spiroazepine, heterocyclic substituted diazepine, aliphatic moiety, etc. Thus, separate searches in the literature as well as in the U.S. Patent Classification System would be required. Each group's compounds are made and used independently of each other and could support separate patents. The compounds differ significantly in chemical structures. One skilled in the art would not

Art Unit: 1624

consider such diverse structures as functional equivalents of each other. The mere fact that there is a single similarity is not in itself a significant reason to render the whole embodiment obvious.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions anticipated by the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Tentative election of a single species within the elected group is further required.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1624

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brenda Coleman whose telephone number is (703) 305-1880. The examiner can normally be reached on Mondays and Tuesdays from 9:00 AM to 3:00 PM and from 5:30 PM to 7:30 PM and on Wednesday thru Friday from 9:00 AM to 6:00 PM.

The fax phone number for this Group is (703) 308-4734 for "unofficial" purposes and the actual number for **OFFICIAL** business is **308-4556**.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-1235.



Brenda Coleman
Primary Examiner AU 1624
January 11, 2002